Updated on 2024/10/03

写真a

 
BABA Taisuke
 
Organization
Nagoya University Hospital Center for Postgraduate Clinical Training and Career Development Assistant professor of hospital
Title
Assistant professor of hospital
External link

Degree 1

  1. Doctor of Philosophy (Medical Science) ( 2019.3   Nagoya University ) 

Research Interests 8

  1. Cholangiocarcinoma

  2. Epigenetics

  3. Metabolomics

  4. AI

  5. Bioinformatics

  6. Pancreatic Cancer

  7. Liquid biopsy

  8. Precision medicine

Research Areas 2

  1. Life Science / Digestive surgery  / Pancreatic cancer, Cholangiocarcinoma

  2. Life Science / Tumor biology  / Pancreatic Cancer, Cholangiocarcinoma, Bioinfomatics, AI, Metabolomics, Epigenetics

Current Research Project and SDGs 2

  1. Development of a novel machine learning model using non-target metabolomics for early cholangiocarcinoma detection

  2. 膵癌分子サブタイプの可塑性の解明とその作用機序に基づく新規診断治療法の開発

Research History 3

  1. Nagoya University   Assistant professor of hospital

    2023.10

  2. Nagoya University   Nagoya University Hospital Gastroenterological Surgery 1   Assistant professor of hospital

    2022.4 - 2023.9

  3. Harvard University, Massachusetts General Hospital   Department of Surgery   Researcher

    2019.4 - 2022.3

      More details

    Country:United States

Education 2

  1. Nagoya University   Surgical Oncology

    2015.4 - 2019.3

      More details

    Country: Japan

  2. Nagoya University

    2001.4 - 2007.3

      More details

    Country: Japan

Awards 2

  1. Travel grant

    2022.7   International Association of Pancreatology  

     More details

    Award type:Award from international society, conference, symposium, etc. 

  2. 若手奨励賞

    2012.10   東海外科学会  

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

 

Papers 13

  1. A lesson in transcriptional plasticity: Classical identity is silenced, but not lost, in pancreatic ductal adenocarcinoma cell lines. Reviewed International coauthorship International journal

    Taisuke Baba, Pascal Finetti; Pancreatic Cancer Group; Keith D Lillemoe, Andrew L Warshaw, Carlos Fernández-Del Castillo, Andrew S Liss

    Gastroenterology   Vol. 163 ( 5 ) page: 1450 - 1453   2022.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1053/j.gastro.2022.07.005

  2. A clinical assessment of three-dimensional-printed liver model navigation for thrice or more repeated hepatectomy based on a conversation analysis

    Igami, T; Maehigashi, A; Nakamura, Y; Hayashi, Y; Oda, M; Yokoyama, Y; Mizuno, T; Yamaguchi, J; Onoe, S; Sunagawa, M; Watanabe, N; Baba, T; Kawakatsu, S; Mori, K; Miwa, K; Ebata, T

    SURGERY TODAY   Vol. 54 ( 10 ) page: 1238 - 1247   2024.10

     More details

    Language:English   Publisher:Surgery Today  

    Purposes: We performed a conversation analysis of the speech conducted among the surgical team during three-dimensional (3D)-printed liver model navigation for thrice or more repeated hepatectomy (TMRH). Methods: Seventeen patients underwent 3D-printed liver navigation surgery for TMRH. After transcription of the utterances recorded during surgery, the transcribed utterances were coded by the utterer, utterance object, utterance content, sensor, and surgical process during conversation. We then analyzed the utterances and clarified the association between the surgical process and conversation through the intraoperative reference of the 3D-printed liver. Results: In total, 130 conversations including 1648 segments were recorded. Utterance coding showed that the operator/assistant, 3D-printed liver/real liver, fact check (F)/plan check (Pc), visual check/tactile check, and confirmation of planned resection or preservation target (T)/confirmation of planned or ongoing resection line (L) accounted for 791/857, 885/763, 1148/500, 1208/440, and 1304/344 segments, respectively. The utterance’s proportions of assistants, F, F of T on 3D-printed liver, F of T on real liver, and Pc of L on 3D-printed liver were significantly higher during non-expert surgeries than during expert surgeries. Confirming the surgical process with both 3D-printed liver and real liver and performing planning using a 3D-printed liver facilitates the safe implementation of TMRH, regardless of the surgeon’s experience. Conclusions: The present study, using a unique conversation analysis, provided the first evidence for the clinical value of 3D-printed liver for TMRH for anatomical guidance of non-expert surgeons.

    DOI: 10.1007/s00595-024-02835-9

    Web of Science

    Scopus

    PubMed

  3. Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer

    Jinno, T; Yamaguchi, J; Ogura, A; Kokuryo, T; Yokoyama, Y; Sunagawa, M; Baba, T; Murata, Y; Ebata, T

    ANTICANCER RESEARCH   Vol. 44 ( 9 ) page: 3757 - 3769   2024.9

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: Recent studies suggest that PD-L1 expression in immune cells, rather than tumor cells, plays a key role in tumor immunity. Trefoil factor family 1 (TFF1) is a secreted protein expressed mainly by the gastrointestinal epithelium and is related to the development of malignant disease. This study investigated the effects of TFF1 on tumor immunity in a xenograft mouse model of colorectal cancer (CRC). Materials and Methods: MC38 cells were implanted in wild-type (WT) and TFF1KO mice, and the tumor microenvironment was investigated using immunohistochemistry. The circulating immune cells were analyzed using flow cytometry. Results: Tumor growth was suppressed in TFF1KO mice. In the tumor microenvironment, CD8- and CD4-positive T cells and CD11c-positive dendritic cells (DCs) were frequently found in TFF1KO mice. When an immune checkpoint inhibitor was administered to these mice, almost half of the tumors in TFF1KO mice showed a complete response. The number of circulating PD-L1/DCs was markedly associated with tumor volume, with TFF1 deletion accelerating this effect and its injection decreasing it. These findings indicate that loss of TFF1 activates tumor immunity via frequent T-cell priming by DCs, and eventually suppresses tumor growth in CRC. In addition, the number of circulating PD-L1/DCs was identified as a predictive marker of checkpoint-inhibiting therapy efficacy. Conclusion: Loss of TFF1 resulted in accelerated immune response to colorectal cancer. Further studies are needed to investigate the precise mechanisms of TFF1 in immunotolerance and develop a novel TFF1-inhibiting immunotherapeutic strategy for CRC.

    DOI: 10.21873/anticanres.17200

    Web of Science

    Scopus

    PubMed

  4. Liver remnant volume to body weight ratio of 0.65% as a lower limit in right hepatic trisectionectomy with bile duct resection

    Hayashi, D; Mizuno, T; Kawakatsu, S; Baba, T; Sando, M; Yamaguchi, J; Onoe, S; Watanabe, N; Sunagawa, M; Ebata, T

    SURGERY   Vol. 175 ( 2 ) page: 404 - 412   2024.2

     More details

    Language:English   Publisher:Surgery (United States)  

    Background: Previous studies have suggested the utility of an indocyanine green plasma clearance rate of the future liver remnant (FLR) (ICGK-F) ≥0.05 in hepatobiliary resection to reduce the surgical risk. The present study aimed to verify whether future liver remnant size rather than ICGK-F matters in extended hepatobiliary resection. Methods: Between 2004 and 2021, patients who underwent right hepatic trisectionectomy with bile duct resection were included. The effect of the FLR volume-to-body weight ratio (FLR/BW) and ICGK-F on posthepatectomy liver failure was evaluated along with other parameters. Results: Among 91 study patients, the median ICGK-F, FLR, and FLR/BW were 0.057 (range, 0.027–0.099), 392 mL (145–705), and 0.78% (0.40–1.37), respectively. Posthepatectomy liver failure occurred in 23 patients. The incidence was 10 (40%) in 25 patients with an ICGK-F <0.05 and 12 (18%) in 65 patients with an ICGK-F ≥0.05 (P = .053); 13 (52%) in 25 patients with a FLR/BW <0.65% and 10 (15%) in 66 patients with a FLR/BW ≥0.65% (P = .001). Multivariate analysis showed that a FLR/BW <0.65% (odds ratio, 11.7; P = .005), age ≥65 years (odds ratio, 31.7; P < .001), and blood loss ≥25 mL/kg (odds ratio, 22.1; P = .004) were independent predictors of posthepatectomy liver failure, but ICGK-F <0.05 was not (P = .499). According to the meeting number of 3 factors, posthepatectomy liver failure incidence was 0 of 22 (0%) in patients with 0 factors, 6 of 43 (14%) in patients with 1, and 17 of 26 (65%) in patients with 2 or 3 (P < .001). Conclusion: A FLR/BW ≥0.65% may serve as a volumetric basis to reduce posthepatectomy liver failure after extended hepatobiliary resection.

    DOI: 10.1016/j.surg.2023.09.037

    Web of Science

    Scopus

    PubMed

  5. The Goal of Intraoperative Blood Loss in Major Hepatobiliary Resection for Perihilar Cholangiocarcinoma Saving Patients From a Heavy Complication Burden Reviewed

    Kawakatsu, S; Mizuno, T; Yamaguchi, J; Watanabe, N; Onoe, S; Sunagawa, M; Baba, T; Igami, T; Yokoyama, Y; Imaizumi, T; Ebata, T

    ANNALS OF SURGERY   Vol. 278 ( 5 ) page: E1035 - E1040   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Surgery  

    Objective: To determine the goal of intraoperative blood loss in hepatectomy for perihilar cholangiocarcinoma. Background: Although massive bleeding can negatively affect the postoperative course, the target value of intraoperative bleeding to reduce its adverse impact is unknown. Methods: Patients who underwent major hepatectomy for perihilar cholangiocarcinoma between 2010 and 2019 were included. Intraoperative blood loss was adjusted for body weight [adjusted blood loss (aBL)], and the overall postoperative complications were evaluated by the comprehensive complication index (CCI). The impact of aBL on CCI was assessed by the restricted cubic spline regression. Results: A total of 425 patients were included. The median aBL was 17.8 (interquartile range, 11.8-26.3) mL/kg, and the CCI was 40.6 (33.7-49.5). Sixty-three (14.8%) patients had an aBL<10 mL/kg, nearly half (45.4%) of the patients were in the range of 10 ≤aBL<20 mL/kg, and 37 (8.7%) patients had an aBL >40 mL/kg. The spline regression analysis showed a nonlinear incremental association between aBL and CCI; CCI remained flat with an aBL under 10 mL/kg; increased significantly with an aBL ranging from 10 to 20 mL/kg; grew gradually with an aBL over 20 mL/kg. These inflection points of 10 and 20 mL/kg were almost consistent with the cutoff values identified by the recursive partitioning technique. After adjusting for other risk factors for the postoperative course, the spline regression identified a similar model. Conclusions: aBL had a nonlinear aggravating effect on CCI after hepatectomy for perihilar cholangiocarcinoma. The primary goal of aBL should be <10 mL/kg to minimize CCI.

    DOI: 10.1097/SLA.0000000000005869

    Web of Science

    Scopus

    PubMed

  6. 特集 肝門部胆管癌の治療戦略update II. 手術の実際 3.肝門部領域胆管癌の切除可能境界

    尾上 俊介, 水野 隆史, 渡辺 伸元, 川勝 章司, 横山 幸浩, 伊神 剛, 山口 淳平, 砂川 真輝, 馬場 泰輔, 江畑 智希

    外科   Vol. 85 ( 11 ) page: 1198 - 1202   2023.10

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka85_1198

    CiNii Research

  7. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer Reviewed International journal

    Kano, MT; Kokuryo, TOSHIO; Baba, TAISUKE; Yamazaki, KIMITOSHI; Yamaguchi, J; Sunagawa, M; Ogura, A; Watanabe, N; Onoe, S; Miyata, K; Mizuno, T; Uehara, K; Igami, T; Yokoyama, Y; Ebata, T; Nagino, M

    ANTICANCER RESEARCH   Vol. 43 ( 3 ) page: 1009 - 1016   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research  

    Background/Aim: α-Bisabolol is an essential oil component extracted from plants, such as chamomile. We have previously reported that α-bisabolol suppressed proliferation, invasion, and motility of pancreas cancer. Cyclodextrin improved the solubility of α-bisabolol, therefore it enabled to administer intravenously. The aim of this study was to clarify the effect of cyclodextrin conjugated α- bisabolol (CD-BSB) and the signals pathways associated with α-bisabolol for pancreatic cancer. Materials and Methods: Human pancreatic cancer cell lines were treated with or without CD-BSB. Cytomorphology and apoptosis were assessed in these treated groups. In addition, several phosphorylated proteins were analyzed to clarify the signal pathway concerning CD-BSB. In subcutaneous xenograft model, tumor volume and Ki-67 expression were evaluated among Control (untreated), CD-BSB, or Gemcitabine (GEM). Results: CD-BSB significantly changed cytomorphology and induced apoptosis in pancreatic cancer cells. CD-BSB suppressed phosphorylation of focal adhesion kinase (FAK). In addition, pFAK 397 was inhibited by CD-BSB in a concentration-dependent manner in cancer cells. In the subcutaneous xenograft models, the tumor volume in the CDBSB groups was lower than Control groups. Ki67-positive cells in CD-BSB treated group were lower than the GEMtreated groups. Conclusion: We clarified the efficiency of CDBSB in xenograft tumor using intravenous administration. α- Bisabolol suppresses phosphorylation of FAK 397 and impairs cytoskeletal polymerization in a pancreatic cancer cell line. Further investigations are required to reveal the precise mechanisms of the antitumor effects of solubilized α- bisabolol to facilitate its clinical application. Our data indicate that solubilized α-bisabolol has therapeutic potential and could improve the prognosis of cancer patients.

    DOI: 10.21873/anticanres.16245

    Web of Science

    Scopus

    PubMed

  8. 特集 血管再建を伴う高難度肝胆膵外科手術 6.肝門部領域胆管癌に対する肝動脈合併切除再建を伴う左側肝切除

    尾上 俊介, 水野 隆史, 渡辺 伸元, 川勝 章司, 横山 幸浩, 伊神 剛, 山口 淳平, 砂川 真輝, 馬場 泰輔, 江畑 智希

    外科   Vol. 85 ( 2 ) page: 145 - 154   2023.2

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka85_145

    CiNii Research

  9. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT). Reviewed International coauthorship International journal

    Bolm L, Zemskov S, Zeller M, Baba T, Roldan J, Harrison JM, Petruch N, Sato H, Petrova E, Lapshyn H, Braun R, Honselmann KC, Hummel R, Dronov O, Kirichenko AV, Klinkhammer-Schalke M, Kleihues-van Tol K, Zeissig SR, Rades D, Keck T, Fernandez-Del Castillo C, Wellner UF, Wegner RE.

    Cancers   Vol. 14 ( 4 ) page: 868   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/cancers14040868.

  10. ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN). Reviewed International coauthorship International journal

    Zelga P, Hernández-Barco YG, Qadan M, Ferrone CR, Baba T, Bolm L, Jah A, Warshaw AL, Lillemoe KD, Balakrishnan A, Castillo CF.

    Pancreatology   Vol. 22 ( 2 ) page: 264 - 269   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.pan.2021.12.012.

  11. Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections. Reviewed International coauthorship International journal

    Roldán J, Harrison JM, Qadan M, Bolm L, Baba T, Brugge WR, Casey BW, Krishnan K, Mino-Kenudson M, Pitman MB, Kambadakone A, Ferrone CR, Warshaw AL, Lillemoe KD, Castillo CF.

    Annals of Surgery   Vol. 277 ( 3 ) page: 491 - 497   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/SLA.0000000000005142

  12. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Reviewed International coauthorship International journal

    Stefanie Lesch, Viktoria Blumenberg, Stefan Stoiber, Adrian Gottschlich, Justyna Ogonek, Bruno L. Cadilha, Zahra Dantes, Felicitas Rataj, Klara Dorman, Johannes Lutz, Clara H. Karches, Constanze Heise, Mathias Kurzay, Benjamin M. Larimer, Simon Grassmann, Moritz Rapp, Alessia Nottebrock, Stephan Kruger, Nicholas Tokarew, Philipp Metzger, Christine Hoerth, Mohamed-Reda Benmebarek, Dario Dhoqina, Ruth Grünmeier, Matthias Seifert, Arman Oener, Öykü Umut, Sandy Joaquina, Lene Vimeux, Thi Tran, Thomas Hank, Taisuke Baba, Duc Huynh, Remco T. A. Megens, Klaus-Peter Janssen, Martin Jastroch, Daniel Lamp, Svenja Ruehland, Mauro Di Pilato, Jasper N. Pruessmann, Moritz Thomas, Carsten Marr, Steffen Ormanns, Anna Reischer, Michael Hristov, Eric Tartour, Emmanuel Donnadieu, Simon Rothenfusser, Peter Duewell, Lars M. König, Max Schnurr, Marion Subklewe, Andrew S. Liss, Niels Halama, Maximilian Reichert, Thorsten R. Mempel, Stefan Endres & Sebastian Kobold

    Nature Biomedical Engineering   Vol. 5 ( 11 ) page: 1246 - 1260   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41551-021-00737-6.

  13. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. Reviewed International journal

    Baba T, Kokuryo T, Yamaguchi J, Yokoyama Y, Uehara K, Ebata T, Nagino M.

    Anticancer Research   Vol. 38 ( 3 ) page: 1427 - 1434   2018.3

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.12367.

▼display all

MISC 1

  1. Metabolic alterations in cholangiocarcinoma. Invited

    Taisuke Baba, Yukihiro Yokoyama, Toshio Kokuryo, Takashi Mizuno, Junpei Yamaguchi, Shunsuke Onoe, Masaki Sunagawa, Nobuyuki Watanabe, Shoji Kawakatsu, Tomoki Ebata

      Vol. 44 ( 5 ) page: 427 - 433   2023.5

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Presentations 7

  1. 膵癌Classicalサブタイプ研究とCAMモデル Invited

    馬場泰輔

    日本患者由来がんモデル学会学術集会2024  2024.8.22  日本患者由来がんモデル学会

     More details

    Event date: 2024.8

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:東京   Country:Japan  

  2. Using omics data for clinical testing - A novel method in the AI era

    2024.4 

     More details

    Event date: 2024.4

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  3. A single sample classifier of Bailey's molecular subtype of PDAC. International conference

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Toshio Kokuryo, Tomoki Ebata

    AACR Special Conference: Pancreatic Cancer  2023.9.27  American Association for Cancer Research

     More details

    Event date: 2023.9

    Language:English   Presentation type:Poster presentation  

    Venue:Boston, US   Country:United States  

  4. Inverse Pairs Boosting (IPB) technique for preclinical cancer detection - A novel approach with urine metabolomics

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Takashi Mizuno, Toshio Kokuryo, Yukihiro Yokoyama, Hizuru Amano, Akinari Hinoki, Hiroo Uchida, Tomoki Ebata

    82nd Annual Meeting of The Japanese Cancer Association  2023.9  Japanese Cancer Association

     More details

    Event date: 2023.9

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Yokohama, JP   Country:Japan  

  5. Novel Urinary Biomarkers for Subclinical Detection of Early-Stage Cholangiocarcinoma. International conference

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Takashi Mizuno, Toshio Kokuryo, Hizuru Amano, Shun Kumano, Takashi Ishigaki, Akinari Hinoki, Tomoki Ebata

    12th AACR-JCA Joint Conference  2022.12  American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA)

     More details

    Event date: 2022.12

    Language:English   Presentation type:Poster presentation  

    Venue:Maui, US   Country:United States  

  6. Remarkable plasticity of classical identity between pancreatic cancer cell lines and tumors. International coauthorship International conference

    Taisuke Baba, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S Liss

    Joint Congress of the 26th Meeting of International Association of Pancreatology and the 53rd Annual Meeting of Japan Pancreas Society  2022.7  IAP & JPS

     More details

    Event date: 2022.7

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Kyoto   Country:Japan  

  7. A comparison between PDX tumors and PDX-derived cell lines highlights the molecular plasticity of pancreatic ductal adenocarcinoma. International coauthorship International conference

    Taisuke Baba, Mari Mino-Kenudson, Keith D Lillemoe, Andrew L Warshaw, Carlos Fernández-Del Castillo, Andrew S Liss.

    American Pancreatic Association Annual Meeting   2021.11  American Pancreatic Association

     More details

    Event date: 2021.11

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Miami, US   Country:United States  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 1

  1. 胆管癌の早期診断を可能にする網羅的尿中メタボローム解析手法の開発

    Grant number:A182  2023.4 - 2024.3

    国立研究開発法人日本医療研究開発機構 (AMED)  橋渡し研究プログラム シーズA 

    江畑智希、國料俊男、山口淳平、水野隆史、砂川真輝、伊藤喜介、檜 顕成

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4500000 ( Direct Cost: \4368933 、 Indirect Cost:\131067 )

KAKENHI (Grants-in-Aid for Scientific Research) 3

  1. 膵癌分子サブタイプの可塑性の解明とその作用機序に基づく新規診断治療法の開発

    Grant number:22K20819  2022.10 - 2024.3

    文部科学省  科学研究費助成事業  2022年度 研究活動スタート支援

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\2860000 ( Direct Cost: \2200000 、 Indirect Cost:\660000 )

  2. Personalized medicine for rare cancers using chicken egg urothelial membrane (CAM) avatars

    Grant number:24K18048  2024.4 - 2027.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  3. Study on the molecular subtypes of bile duct cancer based on RNA-seq analysis.

    Grant number:24K11928  2024.4 - 2027.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s)